Ticagrelor in Post-transplant Patients With Pediatric Hepatic Artery Thrombosis (HAT)

NCT04946929 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-07-01

No results posted yet for this study

Summary

Hepatic artery thrombosis (HAT) represents a major cause of graft loss and mortality after Pediatric liver transplantation. Ticagrelor (a new reversible inhibitor of P2Y12 receptor with faster onset of action and greater platelet inhibition) was used to treat patients with pediatric post-transplant hepatic artery thrombosis (HAT) compared to low molecular weight heparin.

Conditions

  • Hepatic Artery Thrombosis
  • Liver Transplant; Complications
  • Pediatric Disease

Interventions

DRUG

Ticagrelor Oral Tablet [Brilinta]

Ticagrelor, 2-3mg/kg, 12h, p.o.

DRUG

Low molecular weight heparin

half amount low molecular weight heparin

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Hao Feng, MD. Ph.D · Dept. Liver Surgery, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine

  • Chuan Shen, MD · Dept. Liver Surgery, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine

  • Xiaosong Chen, MD · Dept. Liver Surgery, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine

  • Qiang XIA, MD. Ph.D · Dept. Liver Surgery, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Months
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-31
Primary Completion
2022-12-31
Completion
2023-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04946929 on ClinicalTrials.gov